Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 06 January 2026 8:01 am

Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST.

44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation
Date: Wednesday, January 14, 2026
Time: 11:00 – 11:25 a.m. PST
Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California

About Kashiv BioSciences:
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For more information, visit www.kashivbiosciences.com and follow us on LinkedIn.

Kashiv BioSciences executives presenting at the 44th J.P. Morgan Healthcare Conference in San Francisco, January 2026.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260105670990/en/

Contact

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
[email protected]

Heena Dhedhi
Head – Corporate Communications
[email protected]

Company Logo
Company Logo
Read more

IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Conference
  • Trade Show

Trending Articles

  • Billionaire Easyjet founder in line for £800m payday from takeover

  • Pension pressure to help swell UK debt to three times size of economy

  • The former African gold miner taking on the billionaire Issa brothers

  • As it happened: FTSE 100 slump as oil soars; Trump says Iran will be ‘hit hard’ tonight

  • Tesco ‘in talks’ to exit eastern Europe

More from City PM

  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • LivaNova to Announce Second-Quarter 2026 Results

    Business Wire
  • Notice of Multi-Color First Quarter 2026 Financial Results Conference Call

    Business Wire
  • IGI President & CEO Waleed Jabsheh to Present at the 16th Annual East Coast IDEAS Investor Conference on June 10, 2026 in New York City

    Business Wire
  • CRH to Acquire Arcosa; Leading U.S. Provider of Aggregates and Critical Infrastructure Products for $8.5B

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy